drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
An investigational HER2-targeting antibody-drug conjugate comprising a humanized anti-HER2 monoclonal antibody linked via an enzyme-cleavable linker to a topoisomerase I inhibitor payload; after HER2 binding and internalization, the linker is cleaved intracellularly to release the cytotoxic payload, causing DNA damage and cell death.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibody-Drug Conjugates
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
A humanized anti-HER2 monoclonal antibody linked via an intracellularly cleavable linker to a topoisomerase I inhibitor. After HER2 binding and internalization, the linker is cleaved to release the payload, which inhibits topoisomerase I, induces DNA damage, and leads to tumor cell death.
drug_name
TQB2102 injection
nct_id_drug_ref
NCT05735496